Business
Fidson Healthcare Plc and GB Pharma Holdings position pharmaceutical outreach into Nigeria and Beyond!
Fidson Healthcare Plc and GB Pharma Holdings position pharmaceutical outreach into Nigeria and Beyond!.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n\n\nFidson Healthcare Plc and GB Pharma Holdings position pharmaceutical outreach into Nigeria and Beyond!\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nFidson Healthcare Plc and GB Pharma Holdings position pharmaceutical outreach into Nigeria and Beyond!\nPR Newswire\nWASHINGTON, Jan. 27, 2016\n\n\n\nWASHINGTON, Jan. 27, 2016 /PRNewswire/ -- The leading Nigerian pharmaceutical company, Fidson Healthcare Plc, has recently made a giant leap toward addressing Nigeria's pharmaceutical needs by entering into an agreement with the American company, GB Pharma Holdings. Their business agreement is expected to provide Fidson with the guidance it needs to establish its foothold within the US and to develop strategic relationships with other business entities. \n\nOf all these entities, US Pharmacopeia (USP) is the most critical. It will insure Fidson's growth by helping it sustain U.S. and international standards. Founded in 1820, this scientific nonprofit organization will share with Fidson its expertise by overseeing the identity, strength, quality and purity of medicines, food ingredients and dietary supplements that Fidson will manufacture and distribute.\n\nWith the support of GB Pharma Holdings, Immune Therapeutics Incorporation [OTCQB: IMUN], and American Hospitals & Resorts, Fidson will gain from this partnership exclusive distribution rights to the internationally recognized immune therapy LodonalTM (Low Dose Naltrexone). It is expected that such collaboration will bring global recognition to Fidson's pharmaceutical enterprise.\n\nAs Fidson's Managing Director and Chief Executive Officer. Dr. Fidelis Akhagboso Ayebae has turned his company into a leading Nigerian pharmaceutical company, which is publically traded with annual US earnings of $60.5 million, making it one of the largest such pharmaceutical companies in Nigeria.\n\n\"My goal,\" Dr. Ayebae said, \"is to provide Nigerians with excellent quality pharmaceuticals at affordable prices. I am very confident that working with USP will help me achieve this end.\" \n\nTo prepare for major growth...